MARKET

EIGR

EIGR

Eiger
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.96
-0.11
-1.09%
After Hours: 9.96 0 0.00% 16:00 02/27 EST
OPEN
9.91
PREV CLOSE
10.07
HIGH
10.69
LOW
9.50
VOLUME
265.48K
TURNOVER
--
52 WEEK HIGH
15.82
52 WEEK LOW
9.38
MARKET CAP
243.97M
P/E (TTM)
-2.9951
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of EIGR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average EIGR stock price target is 37.17 with a high estimate of 61.00 and a low estimate of 22.00.

EPS

EIGR News

More
  • Ladenburg Thalmann Maintains Buy on Eiger BioPharmaceuticals, Raises Price Target to $31
  • Benzinga · 01/22 13:18
  • Top Insider Buys Highlight for the Week of Jan. 17
  • GuruFocus.com · 01/19 20:04
  • Trade Alert: The Chairman Of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), Thomas Dietz, Has Just Spent US$56k Buying Shares
  • Simply Wall St. · 01/15 10:24
  • Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer
  • PR Newswire · 01/07 13:00

Industry

Biotechnology & Medical Research
-3.78%
Pharmaceuticals & Medical Research
-3.00%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About EIGR

Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials, which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara, Turkey), LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover, Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema.
More

Webull offers kinds of Eiger Biopharmaceuticals Inc stock information, including NASDAQ:EIGR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EIGR stock news, and many more online research tools to help you make informed decisions.